Incidence of renal cell carcinoma in Santiago de Cuba

Rodríguez-Cruzata Lesyibeth

Article ID: 2087
Vol 4, Issue 2, 2023
DOI: https://doi.org/10.54517/urr.v3i1.2087
VIEWS - 37 (Abstract)

Abstract

Introduction: renal parenchymal tumors account for approximately 2-3% of tumors in adults' patients and in turn the 85% of primary kidney tumors. An increased incidence of renal parenchymal tumors has been observed around the world and in Cuba in the last years. It is the most deadly cancer in the urinary tract worldwide. Objective: to identify incidence and the clinical- epidemiological and histopathological features of renal cell carcinoma in the province of Santiago de Cuba. Method: a descriptive and cross-sectional study was conducted concerning renal adenocarcinoma in 88 patients from Santiago de Cuba. Period of study was from January 1, 2012 throughout January 1, 2017. The diagnosis was based on histopathological studies from patients who underwent surgery and died due to this disease. Variables studies were as follow: incidence, age, sex, risk factors, symptoms and signs, histologic type and cancer staging. Results: it was more frequent between the fifth and sixth decades of life and in males. Smoking was the main risk factor. More than 50% of cases were diagnosed incidentally and asymptomatically, although symptoms such as flank pain, hematuria, general symptoms and palpable abdominal mass appeared. Clear cell tumor was the histologic variety most affected. They were diagnosed mainly in stage T3a. Conclusions: family physicians, clinicians, urologists and radiologists are involved in the diagnosis of renal carcinoma, so it is important to be aware of this illness since it can present in the most unsuspected way.


Keywords

adenocarcinoma; kidney; renal cell carcinoma; incidence; diagnosis

Full Text:

PDF



References

1. Campbell Steven C, Lane Brian R. Malignant renal tumors. In: Wein Alan J, et al. Campbell-Walsh Urology. 10maed [Internet]. Mexico: DF; 2015. [cited 16 May 2021]; v.2. p:1431-1509. Available from: https://booksmedicos.org/campbell-walsh- urology-10a-edition/.

2. Calvo Vazquez I, Santander Flores SA, Gonzales Villegas P, Bravo López GM, Yañes Sosa AL, Reyna Blanco I. Radical nephrectomy: incidence of morbidity and mortality in a tertiary level hos-pital. Rev Mex Uro l [Internet]. 2017 Nov-Dec [cited 16 May 2021]; 77(6):446-452. Available from: https://docplayer.es/137750357- Nefrecto-my-radical-radical-incidence-of-morbidity-and-mortality-in-a-third-level-hospital.html.

3. Mahdavifar N, Mohammadian M, Ghonchen M, Salehiniya H. Incidence, Mortality and risk factors of Kidney cancer in the world. World Cancer Res J [Internet]. 2018 [cited 16 May 2021]; 5(1):1-9. Available from: https://www.wcrj.net/wp- con-tent/uploads/sites/5/2018/03/e1013- Inci-dence-Mortality-and-Risk-Factors-of- Kid-ney-Cancer-in-the-World.pdf.

4. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update Eur Urol [Internet]. 2019 [cited 16 May 2021]; 75:799-810. DOI: https://doi.org/10.1016/j.eururo.2019.02.01 1

5. Campbell S, Uzzo R, Allaf M, Bass E, Cadeddu J, Chang A, et al. Renal mass and Localized renal cancer: AUA Guideline. Am Urol Assoc Educ Res [Internet]. 2017 [cited 16 Apr 2021]; 1-50. Availa-ble from: https://www.ncbi.nlm.nih.gov/pubmed/284 79239.

6. Sánchez-Lorenzo IM, Torres-Reyes JE, Espi-nosa-Rondón L, Alvares-Sánchez IM, Pe-ña-Rodríguez H. Characterization of clinical and therapeutic variables in patients with clear renal cell adenocarcinoma. Rev Electron Dr. Zoilo E. Marinello Vidaurreta [Internet]. 2018 [cited 16 May 2021]; 43(4). Available from: http://www.revzoilomarinello.sld.cu/index.p hp/zmv/article/view/1459.

7. Uscanga-Yépez J, Martnez-González A, Sego-via-Sandoval K, Barrera-Juárez E, Gonzá-lez-Oyervides R. Clinical manifestations and on-cologic outcomes of renal cancer in a hospital in northern Mexico. Rev Mex Urol [Internet]. 2018 May-Jun [cited 16 May 2021]; 78(3):176-182. DOI: https://doi.org/10.24245/revmexurol.v78i3. 1929

8. Cancer of the Kidney and Renal Pelvis - SEER Stat Fact Sheets [Internet]. 2020 Oct [cit-ed16May2021].Availablefrom:http://seer.cancer.gov/statfacts/html/kidrp. html.

9. ONEI. Statistical Yearbook of Santiago de Cuba 2016 [Internet]. Santiago de Cuba: National Office of Statistics and Information; 2017. [cited 16 May 2021]. Available from: http://www.onei.gob.cu/sites/default/files/ anuario_est_provincial/00_santiago_de_cub a.pdf.

10. Montironi R, Cheng L, Scarpelli M, Lopez- Beltran A. Pathology and Genetics: The 2016 WHO Classi-fication of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Uro [Internet]. 2016 Jul [cited 16 May 2021]; 70(1):93-105. Available from: https://www.clinicalkey.es/service/content/ pdf/watermarked/1-s2.0- S0302283816002062.pdf?locale=en_US&sear chIndex=

11. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, et al. Clinical Practice Guidelines in Oncology Kidney Cancer. J Natl Compr Canc Netw [Internet]. 2006 Nov [cited 16 May 2021]; 4(10):1072-81. Available from:https://pubmed.ncbi.nlm.nih.gov/19555584/

12. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer [Internet]. 2015 Mar [cited 16 May 2021]; 136(5):E359-86. DOI: https://doi.org/10.1002/ijc.29210

13. Darias Martín JL, Rodríguez Collar TL. Influence of initial tumor stage on survival in patients with renal adenocarcinoma Rev Cubana Med Mil [In-ternet]. 2018 [cited 16 May 2021]; 47(1):33-42. Available from: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/101

14. García García A, Guerra Román F B, García Morales I. Simple enucleation in the treatment of renal tu-mors Rev Cubana Urol [Internet]. 2017 [cited 16 May 2021]; 6(1). Available from: http://www.revurologia.sld.cu

15. Velis J, et al. Risk models for patients with local-ized renal cell carcinoma. Actas Urol Esp [Internet]. 2017 [cited 16 May 2021]; 41(9):564-570. DOI: https://doi.org/10.1016/j.acuroe.2017.08.00 7

16. Gelfond J, et al. Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. Urol Oncol [Internet]. Jul 2018 [cited 16 May 2021]; 36(7):340.e1-340.e6.DOI: https://doi.org/10.1016/j.urolonc.2018.04.0 11

17. Arteche AH. Descriptive epidemiology and surviv-al analysis of kidney cancer in public hospitals of the Autonomous Community of Madrid Doctoral Thesis. Madrid: Universidad Complutense de Ma-drid, Facultad de Medicina; 2017 [cited 16May2021].Availablefrom:https://eprints.ucm.es/id/eprint/47126/1/T39799.pdf

18. Inamura K. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci [Inter-net]. 2017 [cited 16 May 2021]; 18(10). DOI:https://dx.doi.org/10.3390%2Fijms1810219 5

19. Lorente D, Trilla E, Meseguer A, Planas J, Placer J, et al. Systematic review of prognostic factors in re-nal carcinoma. Actas Urol Esp [Internet]. 2017 [cited 16 May 2021]; 41(4):215-225. DOI:http://dx.doi.org/10.1016/j.acuro.2016.08.0 03

20. Lorente ED, Trilla A, Meseguer J, Arévalo S, et al. Value of STAT3c protein as a prognostic factor in clear cell renal carcinoma. Systematic review. Actas Urol Esp [Internet]. 2019 [cited 16 May 2021];43(3):118-123. DOI: https://doi.org/10.1016/j.acuro.2018.08.003

21. Clemmensen T, et al. Pathologic and clinical char-acteristics of early onset renal cell carcinoma. Hu-man Pathology [Inter-net].2018[citado16May2021];74:25-31.DOI:https://doi.org/10.1016/j.humpath.2017.11. 005

22. Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid renal cell carcinoma: population-based study of 879 patients. Clin Gen-itourin Cancer [Internet]. 2019 [cited 16 May 2021]; 17:e447-e453. DOI: https://doi.org/10.1016/j.clgc.2019.01.005

23. Prokopowicz G, Kowski M, Nowakowski K, Bo-gacki R, Bryniarski P, Paradysz A. Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma. Bio Med Res Int [Internet]. 2016 [cited 30 Nov 2021]:8687575.Availablefrom:https://www.hindawi.com/journals/bmri/2016/8687575/

Refbacks

  • There are currently no refbacks.